secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001520138-24-000079
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie's NE3107 shows PD Phase 2a non-motor symptom improvement; AD Phase 3 misses significance but biomarker gains
--------------------------------------------------------------------------------

- PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.
- PD: 26% of NE3107 patients had better morning motor scores vs 0% placebo (p=0.046); younger patients saw >6 point UPDRS advantage.
- AD Phase 3 missed significance per protocol; NE3107 showed 68% slowing of decline on CDR-SB and 26% on ADAS-COG-12.
- AD biomarkers: NE3107 associated with biological age deceleration -3.87 years (p=0.012), reduced fasting glucose and cholesterol.
- Principal component analysis suggests NE3107 may realign metabolic inflammation; data presented at AD/PD 2024 in Lisbon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/0001520138-24-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/bivi-20240301_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-24-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer